SVB Leerink cut shares of Regeneron Pharmaceuticals (NASDAQ:REGN – Get Rating) from an outperform rating to a market perform rating in a report released on Monday, Marketbeat.com reports. They currently have $630.00 price objective on the biopharmaceutical company’s stock.
Other analysts have also issued research reports about the company. Jefferies Financial Group lowered Regeneron Pharmaceuticals to a sell rating and set a $536.00 price objective for the company. in a report on Friday, June 17th. Cantor Fitzgerald assumed coverage on Regeneron Pharmaceuticals in a report on Tuesday, July 12th. They set a neutral rating and a $625.00 price target for the company. Wells Fargo & Company cut their price target on Regeneron Pharmaceuticals from $750.00 to $735.00 and set an overweight rating for the company in a report on Friday, June 3rd. Argus boosted their price objective on Regeneron Pharmaceuticals from $680.00 to $760.00 and gave the company a buy rating in a research report on Tuesday, May 31st. Finally, Morgan Stanley boosted their price objective on Regeneron Pharmaceuticals from $610.00 to $619.00 and gave the company an equal weight rating in a research report on Friday, July 15th. Two equities research analysts have rated the stock with a sell rating, six have assigned a hold rating and twelve have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of Moderate Buy and an average target price of $697.15.
Regeneron Pharmaceuticals Stock Up 0.2 %
Shares of NASDAQ:REGN opened at $587.28 on Monday. The stock has a fifty day simple moving average of $613.60 and a two-hundred day simple moving average of $637.99. The stock has a market capitalization of $63.74 billion, a price-to-earnings ratio of 8.32, a PEG ratio of 1.77 and a beta of 0.31. Regeneron Pharmaceuticals has a 12-month low of $538.01 and a 12-month high of $747.42. The company has a current ratio of 4.76, a quick ratio of 4.09 and a debt-to-equity ratio of 0.14.
Insiders Place Their Bets
In other Regeneron Pharmaceuticals news, EVP Marion Mccourt sold 1,100 shares of the firm’s stock in a transaction that occurred on Monday, May 2nd. The shares were sold at an average price of $656.97, for a total value of $722,667.00. Following the transaction, the executive vice president now directly owns 19,644 shares of the company’s stock, valued at approximately $12,905,518.68. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the business’s stock in a transaction on Monday, May 2nd. The shares were sold at an average price of $650.78, for a total value of $65,078.00. Following the completion of the transaction, the director now owns 22,182 shares in the company, valued at $14,435,601.96. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Marion Mccourt sold 1,100 shares of the business’s stock in a transaction on Monday, May 2nd. The stock was sold at an average price of $656.97, for a total transaction of $722,667.00. Following the completion of the transaction, the executive vice president now owns 19,644 shares of the company’s stock, valued at approximately $12,905,518.68. The disclosure for this sale can be found here. Insiders have sold 2,300 shares of company stock valued at $1,434,281 in the last ninety days. 8.99% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Regeneron Pharmaceuticals
Institutional investors and hedge funds have recently bought and sold shares of the stock. Core Alternative Capital lifted its position in Regeneron Pharmaceuticals by 800.0% in the first quarter. Core Alternative Capital now owns 36 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 32 shares during the last quarter. Addison Advisors LLC raised its holdings in shares of Regeneron Pharmaceuticals by 220.0% in the first quarter. Addison Advisors LLC now owns 48 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 33 shares during the last quarter. ACG Wealth purchased a new stake in shares of Regeneron Pharmaceuticals in the second quarter valued at about $30,000. Delos Wealth Advisors LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $33,000. Finally, Benjamin Edwards Inc. purchased a new stake in shares of Regeneron Pharmaceuticals in the fourth quarter valued at about $33,000. 83.83% of the stock is owned by hedge funds and other institutional investors.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
- Get a free copy of the StockNews.com research report on Regeneron Pharmaceuticals (REGN)
- Palantir Stock is Showing Signs of Life
- Taking a Look at Nvidia’s Stock Amidst The Semiconductor Chip Gut
- The Institutions Like The Color Of PPG Industries
- What Investors Need to Know to Beat the Market
- Alcoa Is Well-Positioned For 2022 and 2023
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.